

Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers.

Cancer Discov. 2020 <https://pubmed.ncbi.nlm.nih.gov/32958578/>

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.

Lancet Oncol. 2020 <https://pubmed.ncbi.nlm.nih.gov/32919527/>

A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations.

Eur J. Cancer 2019 <https://pubmed.ncbi.nlm.nih.gov/31543384/>

Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance.

Clin Cancer Res. 2020 <https://pubmed.ncbi.nlm.nih.gov/31591187/>

Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favourable Outcomes.

Cancer Discov. 2020 <https://pubmed.ncbi.nlm.nih.gov/32238360/>

Genomic landscape of platinum resistant and sensitive testicular cancers.

Nat Commun. 2020 <https://pubmed.ncbi.nlm.nih.gov/32366847/>

MRI Tumour Regression Grade and Circulating Tumour DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer.

Clin Cancer Res. 2020 <https://pubmed.ncbi.nlm.nih.gov/31852830/>

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.

Nat Commun. 2020 <https://pubmed.ncbi.nlm.nih.gov/32471999/>

Representative Sequencing: Unbiased Sampling of Solid Tumour Tissue.

Cell Rep. 2020 <https://pubmed.ncbi.nlm.nih.gov/32375028/>

The KDR (VEGFR-2) Genetic Polymorphism Q472H and c-KIT Polymorphism M541L Are Associated with More Aggressive Behaviour in Astrocytic Gliomas

Cancer Genomics & Proteomics 2020 <https://pubmed.ncbi.nlm.nih.gov/33099473/>

Identification of genetic targets in acute myeloid leukaemia for designing targeted therapy.

Br J Haematol. 2020 <https://pubmed.ncbi.nlm.nih.gov/33022753/>

Evaluation of Xpert® BCR-ABL Ultra for the confirmation of BCR-ABL1 international scale conversion factors for the molecular monitoring of chronic myeloid leukaemia.

Int J Lab Hematol. 2020 <https://pubmed.ncbi.nlm.nih.gov/32990400/>